玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液治疗老年白内障术后干眼症的临床效果观察

Observation on the Clinical Effect of Sodium Hyaluronate Eye Drops Combined with Recombinant Human Epidermal Growth Factor Eye Drops in the Treatment of Elderly Xerophthalmia After Cataract Surgery

目的探讨玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液治疗老年白内障术后干眼症的临床效果。方法选取2018年5月至2020年4月我院收治的老年白内障术后干眼症患者86例,随机分为两组各43例。对照组采用玻璃酸钠滴眼液治疗,实验组采用玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液治疗。比较两组的临床效果以及治疗前后的FL评分、泪液分泌长度及BUT。结果实验组的治疗总有效率为97.67%,显著高于对照组的83.72%(P<0.05)。治疗后,实验组的FL评分、泪液分泌长度均显著低于对照组,BUT显著长于对照组(P<0.05)。结论玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液治疗老年白内障术后干眼症的效果显著,可有效促进患者泪膜稳定,减少泪液分泌,减轻角膜损伤。

Objective To explore the clinical effect of sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops in the treatment of elderly xerophthalmia after cataract surgery.Methods 86 cases of elderly patients with xerophthalmia after cataract surgery admitted to our hospital from May 2018 to April 2020 were selected and randomly divided into two groups,with 43 cases in each group.The control group was treated with sodium hyaluronate eye drops,and the experimental group was treated with sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops.The clinical efficacy,and the FL scores,tear secretion length and BUT before and after treatment were compared between two groups.Results The total effective rate of treatment of experimental group was 97.67%,significantly higher than 83.72%of control group(P<0.05).After treatment,the FL score and tear secretion length of experimental group were significantly lower than those of control group,and BUT was significantly longer than that of control group(P<0.05).Conclusions Sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops in the treatment of elderly xerophthalmia after cataract surgery have significant effect,and can effectively promote the tear film stability,reduce tear secretion,and reduce corneal injury of patients.